Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar;9(3):1742–1751. doi: 10.21037/tcr.2020.03.26

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

2020 Translational Cancer Research. All rights reserved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

PMC Copyright notice

LSZ inhibits tumor formation by increasing PTEN levels and blocking the Wnt/β-catenin pathway in vivo. The mice were randomly divided into 2 groups (n=10): LSZ group; mice were injected intraperitoneally (i.p.) with 70 mg/kg LSZ; Control group, mice were subjected to the same volume of physiological saline daily. (A) Tumor growth; (B) tumor weight; (C) tumor volume; (D) the protein levels of PTEN, GSK-3β, Wnt, and β-catenin were detected by western blotting in the control group and LSZ group. (**, P<0.01; ***, P<0.001 vs. control group); (E) the expression level of PTEN was detected by IHC in tumor tissues from the control group and the LSZ group. LSZ, ligustrazine; LC, lung cancer.